# Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation

> **NCT01881984** · PHASE1 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 4 (actual)

## Conditions studied

- Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

## Interventions

- **DRUG:** Ravicti

## Key facts

- **NCT ID:** NCT01881984
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2017-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01881984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01881984, "Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01881984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*